Related Experiment Videos
Antihypertensive therapy and coronary prevention
1Division of Cardiology, Medizinische Universitätsklinik Karl-Franzens University, Graz, Austria.
Insights
Antihypertensive therapy effectively reduces cardiovascular risk in malignant hypertension. Further research is needed to demonstrate coronary prevention benefits in mild to moderate hypertension using newer agents.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Antihypertensive therapy is established for malignant hypertension but lacks proven cardiovascular risk reduction in mild to moderate cases.
- Previous trials may be limited by methodology, statistical power, medication side effects, or overlooking left ventricular hypertrophy regression.
- Current primary prevention research often uses beta-blockers and diuretics, which have potential adverse metabolic effects and do not regress left ventricular hypertrophy.
Purpose of the Study:
- To evaluate the effectiveness of antihypertensive therapy in reducing cardiovascular risk in patients with mild to moderate hypertension.
- To explore reasons for the lack of demonstrated coronary prevention in previous large-scale trials for non-malignant hypertension.
- To identify newer antihypertensive agents that may offer improved cardiovascular protection and regress left ventricular hypertrophy.
Main Methods:
- Review of large-scale clinical trials on antihypertensive therapy and cardiovascular outcomes.
- Analysis of factors potentially influencing trial results, including methodological issues and medication properties.
- Examination of the role of left ventricular hypertrophy regression in cardiovascular risk reduction.
Main Results:
- Cardiovascular risk reduction is demonstrated in malignant hypertension but not consistently in mild to moderate hypertension.
- Potential limitations in prior studies include methodological flaws, statistical constraints, and adverse drug effects.
- Beta-blockers and diuretics, commonly used, may have unfavorable metabolic profiles and do not regress left ventricular hypertrophy.
Conclusions:
- Future research should focus on newer antihypertensive agents like calcium channel blockers and angiotensin-converting enzyme inhibitors for non-malignant hypertension.
- These newer agents have shown potential to regress left ventricular hypertrophy and possess favorable metabolic profiles.
- Further investigation is warranted to confirm their efficacy in primary cardiovascular prevention in patients with mild to moderate hypertension.
Abstract:
Antihypertensive therapy reduces cardiovascular risk in patients with malignant hypertension, but has not yet been shown to reduce risk in patients with mild to moderate hypertension. The lack of significant coronary prevention in the latter group, in large-scale trials, may have resulted from methodologic problems, statistical limitations, the adverse effects of antihypertensive medications, or failure to recognize the prognostic importance of concomitant regression of left ventricular hypertrophy. To date, primary prevention studies have focused on the use of beta-blockers and diuretics, both of which may have adverse metabolic effects and neither of which is capable of modifying left ventricular hypertrophy. Future research should be directed toward evaluating coronary prevention in patients with nonmalignant hypertension who have been treated with newer agents, such as calcium channel blockers and angiotensin-converting enzyme inhibitors, each of which has been shown to regress left ventricular hypertrophy and not to have adverse metabolic effects.